# | Title | Journal | Year | Citations |
---|
1 | Polypharmacology: drug discovery for the future | Expert Review of Clinical Pharmacology | 2013 | 362 |
2 | Corticosteroids in brain cancer patients: benefits and pitfalls | Expert Review of Clinical Pharmacology | 2011 | 263 |
3 | Hydrogen sulfide and inflammation: the good, the bad, the ugly and the promising | Expert Review of Clinical Pharmacology | 2011 | 262 |
4 | A perspective on the epidemiology of acetaminophen exposure and toxicity in the United States | Expert Review of Clinical Pharmacology | 2014 | 196 |
5 | Therapeutic potential of KCa3.1 blockers: recent advances and promising trends | Expert Review of Clinical Pharmacology | 2010 | 172 |
6 | From pharmaceuticals to nutraceuticals: bridging disease prevention and management | Expert Review of Clinical Pharmacology | 2019 | 170 |
7 | The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system | Expert Review of Clinical Pharmacology | 2011 | 163 |
8 | TargetingN-methyl-D-aspartate receptors for treatment of neuropathic pain | Expert Review of Clinical Pharmacology | 2011 | 162 |
9 | Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence | Expert Review of Clinical Pharmacology | 2021 | 144 |
10 | Homocysteine and the pathogenesis of atherosclerosis | Expert Review of Clinical Pharmacology | 2015 | 143 |
11 | Nutraceuticals - shedding light on the grey area between pharmaceuticals and food | Expert Review of Clinical Pharmacology | 2018 | 140 |
12 | Modeling and predicting drug pharmacokinetics in patients with renal impairment | Expert Review of Clinical Pharmacology | 2011 | 138 |
13 | Dupilumab for treatment of atopic dermatitis | Expert Review of Clinical Pharmacology | 2018 | 135 |
14 | Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews | Expert Review of Clinical Pharmacology | 2018 | 134 |
15 | The asthma–chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations | Expert Review of Clinical Pharmacology | 2013 | 133 |
16 | Blinding and expectancy confounds in psychedelic randomized controlled trials | Expert Review of Clinical Pharmacology | 2021 | 133 |
17 | Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications | Expert Review of Clinical Pharmacology | 2017 | 128 |
18 | STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: origin and progress | Expert Review of Clinical Pharmacology | 2020 | 121 |
19 | Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis | Expert Review of Clinical Pharmacology | 2012 | 116 |
20 | Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy | Expert Review of Clinical Pharmacology | 2012 | 114 |
21 | Mesalamine in the treatment and maintenance of remission of ulcerative colitis | Expert Review of Clinical Pharmacology | 2012 | 112 |
22 | Proton pump inhibitors: use and misuse in the clinical setting | Expert Review of Clinical Pharmacology | 2018 | 112 |
23 | Understanding and preventing drug–drug and drug–gene interactions | Expert Review of Clinical Pharmacology | 2014 | 110 |
24 | Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? | Expert Review of Clinical Pharmacology | 2015 | 108 |
25 | Pharmacovigilance in resource-limited countries | Expert Review of Clinical Pharmacology | 2015 | 107 |
26 | Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives | Expert Review of Clinical Pharmacology | 2010 | 102 |
27 | Perils and pitfalls of long-term effects of proton pump inhibitors | Expert Review of Clinical Pharmacology | 2013 | 101 |
28 | Sex and gender influences on pharmacological response: an overview | Expert Review of Clinical Pharmacology | 2014 | 99 |
29 | Therapeutic drug monitoring of anti-infective agents in critically ill patients | Expert Review of Clinical Pharmacology | 2016 | 98 |
30 | NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs | Expert Review of Clinical Pharmacology | 2018 | 98 |
31 | Innovative clinical trial design for pediatric therapeutics | Expert Review of Clinical Pharmacology | 2011 | 96 |
32 | Cancer prevention and treatment using combination therapy with natural compounds | Expert Review of Clinical Pharmacology | 2020 | 92 |
33 | Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms | Expert Review of Clinical Pharmacology | 2015 | 91 |
34 | Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response | Expert Review of Clinical Pharmacology | 2012 | 89 |
35 | LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature | Expert Review of Clinical Pharmacology | 2018 | 88 |
36 | Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity | Expert Review of Clinical Pharmacology | 2010 | 84 |
37 | Adverse effects in women: implications for drug development and regulatory policies | Expert Review of Clinical Pharmacology | 2011 | 84 |
38 | Psychopharmacological advances in eating disorders | Expert Review of Clinical Pharmacology | 2018 | 84 |
39 | Clinical and pharmacological profile of benznidazole for treatment of Chagas disease | Expert Review of Clinical Pharmacology | 2018 | 84 |
40 | Acid peptic diseases: pharmacological approach to treatment | Expert Review of Clinical Pharmacology | 2009 | 83 |
41 | PD-1/PD-L1 pathway inhibitors in advanced prostate cancer | Expert Review of Clinical Pharmacology | 2018 | 83 |
42 | Managing the adverse effects of nonsteroidal anti-inflammatory drugs | Expert Review of Clinical Pharmacology | 2011 | 82 |
43 | Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®) | Expert Review of Clinical Pharmacology | 2014 | 81 |
44 | The pharmacological management of metabolic syndrome | Expert Review of Clinical Pharmacology | 2018 | 80 |
45 | Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs | Expert Review of Clinical Pharmacology | 2020 | 79 |
46 | Nanoparticles as potential clinical therapeutic agents in Alzheimer’s disease: focus on selenium nanoparticles | Expert Review of Clinical Pharmacology | 2017 | 77 |
47 | G-quadruplex interacting small molecules and drugs: from bench toward bedside | Expert Review of Clinical Pharmacology | 2014 | 76 |
48 | Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF | Expert Review of Clinical Pharmacology | 2014 | 75 |
49 | Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia | Expert Review of Clinical Pharmacology | 2018 | 75 |
50 | Therapeutic potential of new hydrogen sulfide-releasing hybrids | Expert Review of Clinical Pharmacology | 2011 | 73 |